Retrieved on:
Monday, December 11, 2023
ESMO,
Neoplasm,
Immune system,
LILRB2,
CD47,
HLA,
Alpha globulin,
Doctor of Philosophy,
Therapy,
KIR3DL1,
CDO,
Cancer,
Inflammation,
Myelocyte,
CSO,
Patient,
LILRB1 Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
Key Points:
- Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
- “We already have encouraging in vitro data demonstrating potent anti-tumor efficacy and primary cell data demonstrating an enhanced safety profile compared to competing CD47 targeting molecules,” said Osiris Marroquin Belaunzaran, PhD, CSO and co-founder of ImmunOs Therapeutics.
- “We believe that HLA molecules can serve as a versatile backbone to develop novel therapies capable of stimulating the immune system of cancer patients to eliminate tumor cells.
- Moreover, we are also utilizing specific HLA molecules to develop novel therapies to treat inflammatory diseases.”
Retrieved on:
Tuesday, October 24, 2023
ESMO,
Therapy,
Infrared spectroscopy correlation table,
Trial of the century,
KIR3DL1,
Pembrolizumab,
PD-1,
Inflammation,
Pharmacokinetics,
LILRB1,
LILRB2,
ILT2,
DLT,
Safety,
Cancer,
CMO,
ILT4,
Patient,
Immuno-psychiatry,
Pharmaceutical industry,
MD The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
Key Points:
- The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
- A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level.
- The Phase 1a/b trial is expected to enroll over 120 patients.
- "We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics.
Retrieved on:
Tuesday, October 17, 2023
LILRB1,
Merck Sharp & Dohme Federal Credit Union,
Immuno-psychiatry,
Pembrolizumab,
Inflammation,
Therapy,
Merck & Co.,
Safety,
ILT4,
Cancer,
LILRB2,
Merck,
HLA,
KIR3DL1,
ILT2,
Patient,
Pharmaceutical industry,
MD IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
Key Points:
- IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
- ImmunOs is currently enrolling patients in the Phase 1a/b trial, initiated earlier this year, to evaluate the potential of IOS-1002 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced solid tumors.
- “We are pleased to enter into this agreement for our ongoing Phase 1a/b trial of IOS-1002,” said Christoph Renner, M.D., Chief Medical Officer, and co-founder of ImmunOs.
- KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Retrieved on:
Tuesday, September 19, 2023
Process,
Change,
University,
Therapy,
Senior,
CMC,
Cancer,
Immuno AG,
MBA,
Research,
University residence hall network,
Doctor of Philosophy,
HSG,
Molecular Partners,
Novartis,
Biology,
FDA,
Technical,
Inflammation,
Pharmaceutical industry,
Vaccine,
Tisagenlecleucel,
MD In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.
Key Points:
- In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.
- We are excited to have her join the team and lead our CMC and technical development efforts to develop and manufacture novel protein- and antibody-based therapies," said Steve Coats, PhD, Chief Development Officer at ImmunOs.
- Her breadth and depth of expertise in technical development, manufacturing and operations will be important for advancing our first-in-class pipeline of multi-functional immunotherapies to and through clinical development."
- "I believe that ImmunOs´ expertise in pioneering HLA-based therapeutics focusing on both oncology and immunology, led by IOS-1002, ImmunOs´ lead clinical candidate in oncology, is at the forefront of current research," said Dr. Constanze Guenther, Senior Vice President, CMC and Technical Development at ImmunOs.
LILRB1,
ILT2,
University,
Therapy,
LILRB2,
HLA,
University of Melbourne,
Cancer,
Pharmacokinetics,
Immuno-psychiatry,
ILT4,
Patient,
Immune system,
Peter MacCallum Cancer Centre,
Trial of the century,
KIR3DL1,
Safety,
Vaccine,
Pharmaceutical industry Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.
Key Points:
- Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.
- IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the treatment of advanced solid tumors.
- Primary endpoints of the current Phase 1a, first-in-human, open-label, non-randomized, multicenter study will be the safety and tolerability of IOS-1002.
- "We are excited that our lead compound IOS-1002 has entered into a first-in-human trial and that patients are being dosed," said Sean R. Smith, CEO of ImmunOs Therapeutics.
Oncology,
Therapy,
HLA,
Stanford University,
Cancer,
Coronavirus Scientific Advisory Board,
Immuno AG,
Immunotherapy,
Doctor of Philosophy,
Associate,
MD Anderson Cancer Center,
Memorial Sloan Kettering Cancer Center,
Memorial,
University,
Michael J. Curran,
Immune system,
FDA,
Pharmaceutical industry,
Vaccine,
MD Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD , has been appointed Chairman of the Company´s Scientific Advisory Board.
Key Points:
- Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD , has been appointed Chairman of the Company´s Scientific Advisory Board.
- In addition to Dr. Curran, Taha Merghoub, PhD, Ulf Petrausch, MD, and Paul Bowness, MD, PhD, currently serve as Scientific Advisors to ImmunOs.
- "We are proud to have Mike Curran chair our Scientific Advisory Board to support the development of our pipeline programs in both immuno-oncology and autoimmune diseases," said Sean R. Smith, Chief Executive Officer at ImmunOs.
- "I am excited to help ImmunOs advance their first-in-class therapeutics, including the lead oncology program, IOS-1002, which targets multiple myeloid checkpoints," said Dr. Curran.
Retrieved on:
Wednesday, April 12, 2023
Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer.
Key Points:
- Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer.
- ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
- "We at ImmunOs are very satisfied with the work done by ProBioGen.
- The tireless effort of the ProBioGen team has enabled ImmunOs to start clinical development as planned and to meet our milestones," said Jeff Abbey, Chief Operating Officer of ImmunOs Therapeutics.
Retrieved on:
Tuesday, January 17, 2023
ILT2,
Degenerative disease,
Schlieren,
ILT4,
LILRB2,
TGA,
Therapeutic Goods Administration,
Therapy,
Immuno-psychiatry,
KIR3DL1,
Pharmacokinetics,
Safety,
Macrophage,
NK,
HLA,
Patient,
Cancer,
PD-1,
Pharmaceutical industry In the trial, the compound will be administered at various dose levels to patients with advanced solid tumors either as monotherapy or in combination with a PD-1 monoclonal antibody.
Key Points:
- In the trial, the compound will be administered at various dose levels to patients with advanced solid tumors either as monotherapy or in combination with a PD-1 monoclonal antibody.
- "Advancing our lead compound IOS-1002 into a first-in-human trial is a major milestone for our team and provides a potential new option for patients," said Sean R. Smith, CEO of ImmunOs Therapeutics.
- "We are excited about the opportunity to evaluate IOS-1002 in patients, as the compound addresses key challenges in cancer immunotherapy.
- We believe it has the potential to help patients with advanced solid tumors who have no further treatment options."
Retrieved on:
Tuesday, November 15, 2022
Degenerative disease,
Phagocytosis,
LILRB2,
Immune system,
Macrophage,
Lightspeed Venture Partners,
Antibody,
HLA,
Therapy,
Patient,
PEGS,
KIR,
Protein,
Autoimmunity,
LILRB1,
NK,
ILT4,
Cancer,
KIR3DL1,
ILT2,
HCV,
HIV,
Immuno-psychiatry,
Lymphatic system,
Pharmaceutical industry,
Vaccine,
MD November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.
Key Points:
- November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.
- The presented data supports IOS-1002 as a first-in-class multi-functional agent which will enter a Phase 1 trial later this year.
- "We are excited that our lead program IOS-1002 has generated such promising non-clinical data both as a monotherapy and in combination with anti-PD-1," added Sean R. Smith, Chief Executive Officer of ImmunOs Therapeutics.
- ImmunOs lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.
